RxDoctor Payments Data

Bobby Kang, DO

Family Medicine · Enid, OKNPI 1538364005

Payments from drug & device makers

$570in general payments, 2019–2025

Across 37 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$200
  • Gilead$125
  • Pfizer$55
  • AstraZeneca$50
  • Johnson & Johnson$33
  • Novo Nordisk$31
  • plus $75 from 4 others

What the payments were for

  • Food & beverage$55397%
  • Education$173%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$570 in reported general payments places this provider in the 55th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$184,659
Medicare patients
175
Services billed
11,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide36$37,661
OzempicSemaglutide37$36,448
EliquisApixaban38$33,560
JardianceEmpagliflozin42$30,282
FarxigaDapagliflozin Propanediol26$24,148
JanuviaSitagliptin Phosphate30$22,258
TrulicityDulaglutide16$19,208
MyrbetriqMirabegron32$18,878
JanumetSitagliptin Phos/Metformin Hcl17$13,783
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,432
Tramadol Hcl371$6,388
InvokametCanagliflozin/Metformin Hcl11$6,192
Gabapentin371$5,325
VerquvoVericiguat11$5,207
TradjentaLinagliptin12$4,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Verquvo$15$41,24858 claims
PfizerEliquis, Premarin$55$36,59449 claims
Novo NordiskOzempic$31$36,44837 claims
Boehringer IngelheimJardiance, Tradjenta$20$35,20454 claims
AstraZenecaFarxiga, Breztri Aerosphere$50$32,58039 claims
Johnson & JohnsonInvokamet$33$6,19211 claims
AbbVieSynthroid$200$4,67456 claims
GSKBreo Ellipta$25$4,11111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Enid

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →